00:47:37 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 165,020,533
Close 2022-05-30 C$ 0.86
Market Cap C$ 141,917,658
Recent Sedar Documents

Cybin submits IND application to FDA for CYB003 trial

2022-05-31 10:05 ET - News Release

Mr. Doug Drysdale reports

CYBIN SUBMITS IND APPLICATION TO FDA FOR ITS PHASE 1/2A FIRST-IN-HUMAN TRIAL OF CYB003 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Cybin Inc. has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (MDD).

"Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly. Based on preclinical studies, our proprietary psilocybin analog has the potential to offer numerous advantages over classic psilocybin with the potential to ultimately provide better outcomes for people suffering with MDD," said Doug Drysdale, chief executive officer of Cybin. "This FDA submission is the next major step in the advancement of CYB003, and we continue to work tirelessly to bring this innovative therapeutic option to people as quickly as possible. We look forward to continuing to work with the FDA to initiate the phase 1/2a trial in mid-2022."

About the CYB003 phase 1/2a trial

The phase 1/2a trial is a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD. Subjects will receive two administrations (placebo/active and active/active) and a response/remission will be assessed at week 3 (after single dose) and at week 6 (after receiving a second dose). Using the Montgomery-Asberg depression rating scale, the trial will assess rapid onset of antidepressant effect on the day of dosing. The study will also evaluate the benefit of more than one administration and will provide pharmacokinetic (PK) and safety data. The trial design will allow for people to continue their treatment with selective serotonin reuptake inhibitors (SSRIs). An optional open-label follow-up study (up to 12 weeks) will allow an assessment of durability of treatment effects.

"Through this phase 1/2a trial, we are primarily looking to demonstrate the improved PK and safety profile of CYB003, as well as efficacy. We have designed the trial to allow people to continue to take their antidepressant medication, which will also allow us to assess the effect of CYB003 on people who are treated with an SSRI. At this time, we expect to have a PK and safety data readout by the end of 2022," concluded Mr. Drysdale.

The company has engaged Clinilabs Drug Development Corp., a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the phase 1/2a clinical trial of CYB003.

About CYB003

CYB003 is derived from psilocybin, which is part of a family of molecules called indolamines that include more common neurotransmitters, such as serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain barrier. Given its structural similarity to serotonin, psilocin can easily activate the serotonin 5-HT2A receptor. CYB003 is a deuterated psilocybin analog designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability. CYB003 has the potential to effectively treat MDD and alcohol use disorder.

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.